A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASSET
- 09 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2016 Planned End Date changed from 1 Oct 2017 to 1 Feb 2019.
- 01 Sep 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Feb 2018.